ClinConnect ClinConnect Logo
Search / Trial NCT00993018

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Launched by JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. · Oct 8, 2009

Trial Information

Current as of June 09, 2025

Terminated

Keywords

Diabetic Neuropathy Diabetic Painful Neuropathy Jnj 42160443 Neuropathic Pain Pain Pharmacokinetics

ClinConnect Summary

This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), dose-ranging study (study carried out at different doses) to evaluate the analgesic efficacy, safety, and tolerability of multiple doses of JNJ-42160443 in patients with neuropathic pain, followed by a double-blind safety ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Chronic neuropathic pain (pain persistent for greater than 6 months) that is moderate to severe in the opinion of the investigator
  • Currently taking neuropathic pain medication limited to maximal allowed doses according to guidelines provided, but are not adequately controlled by standard of care
  • Currently not taking neuropathic pain medications because they are intolerable to, or not willing to use, standard of care
  • Mean average pain intensity score of at least 5, but less than 10, over 7 consecutive days on an 11-point numerical rating scale
  • Pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus
  • Required to have stable glycemic control
  • Exclusion Criteria:
  • Patients with severe diabetic neuropathy defined by severe autonomic dysfunction or blood pressure instability Separate pain condition (e.g., joint osteoarthritis) that is more severe than their pain due to their diagnosis of Diabetic Peripheral Neuropathy
  • Patients with evidence of another neuropathic pain not under the study, such as pain resulting from post-traumatic neuralgia, post-surgical neuropathy, complex regional pain, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, Human Immunodeficiency Virus (HIV) infection
  • Major surgeries, trauma, and non-healing wounds/ulcers within 3 months prior to study medication
  • History of severe traumatic brain injury within the past 15 years
  • Other peripheral neuropathy, parasthesia or dyesthesia or previously diagnosed neurological condition causing these symptoms not related with diabetic painful neuropathy under study

About Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is a leading global biopharmaceutical company dedicated to advancing medical innovation and improving patient outcomes. As a subsidiary of Johnson & Johnson, the organization focuses on the research, development, and commercialization of novel therapeutics across various therapeutic areas, including immunology, oncology, neuroscience, and infectious diseases. With a commitment to scientific excellence and collaboration, the company leverages cutting-edge technologies and a robust pipeline to address unmet medical needs and deliver transformative solutions that enhance the quality of life for patients worldwide.

Locations

San Antonio, Texas, United States

Winston Salem, North Carolina, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Baltimore, Maryland, United States

Toledo, Ohio, United States

Long Beach, California, United States

Austin, Texas, United States

Fresno, California, United States

Albany, New York, United States

Walnut Creek, California, United States

Syracuse, New York, United States

Redondo Beach, California, United States

Tulsa, Oklahoma, United States

La Jolla, California, United States

Winston Salem, North Carolina, United States

Plano, Texas, United States

Jonesboro, Arkansas, United States

Bradenton, Florida, United States

Renton, Washington, United States

Tullahoma, Tennessee, United States

Tustin, California, United States

Greer, South Carolina, United States

Palm Beach Gardens, Florida, United States

Patients applied

0 patients applied

Trial Officials

Johnson & Johnson Pharmaceutical Research and Development, L. L. C. Clinical Trial

Study Director

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials